血清巨噬细胞抑制因子-1在肺癌诊断中的临床应用  

Clinical Application of Serum Macrophage Inhibitory Cytokine-1 for Diagnosis of Lung Cancer

作　　者：沈迪[1] 王小兵[1] 车轶群[1] 刘秋颖[1] 许潇天[1] 张伟[1] 齐军[1] 

机构地区：[1]北京协和医学院中国医学科学院肿瘤医院,北京100021

出　　处：《中国肿瘤》2015年第5期421-425,共5页China Cancer

基　　金：国家高技术研究发展863计划资助项目(2008AA02Z415);北京希望马拉松专项基金临床课题(LC2012A12);国家自然科学基金(81441080)

摘　　要：[目的]研究巨噬细胞抑制因子-1（MIC-1）血清水平在肺癌诊断中的临床应用价值。[方法 ]采用ELISA方法检测324例肺癌患者、48例肺良性疾病患者和229例正常对照人群血清MIC-1浓度,并检测肺癌患者血清CEA、CA125、NSE、CYFRA21-1和SCC浓度。[结果]肺癌组患者血清中MIC-1浓度显著性高于正常对照组（P〈0.001）和肺良性疾病组（P〈0.001）。MIC-1诊断肺癌的敏感度和特异性分别为71.3%和96.5%。MIC-1诊断肺癌的敏感度优于已有标志物CEA、CA125、NSE、SCC和CYFRA21-1;在肺癌早期（Ⅰ～Ⅱ期）阶段,MIC-1的敏感度优于其他5种标志物的联合诊断（Ⅰ期：66.7%vs 47.6%,Ⅱ期：71.7%vs 65.0%）;6种标志物联合诊断则能使Ⅰ期和Ⅱ期肺癌诊断敏感度分别提高至77.1%和83.3%。[结论]MIC-1可能成为比较理想的肺癌诊断标志物。[Purpose] To investigate the clinical value of macrophage inhibitory cytokine-1 （MIC-1） as a serum tumor marker for the diagnosis of lung cancer. [ Methods ] The double antibody sand- wich ELISA was used to detect serum MIC-1 level in 324 cases with lung cancer,48 cases with benign pulmonary disease and 229 healthy persons. Serum CEA,CA125,NSE,CYFRA21-1and SCC levels were also detected. [Results] MIC-1 concentration in lung cancer group was signifi- cantly higher than that in healthy persons group （P〈0.001）and in benign disease group （P〈0.001）. The specificity and sensitivity of MIC-1 for lung cancer were 96.5% and 71.3% respectively. The sensitivity of MIC-1 for early stage of lung cancer was higher than that of CEA ,.CA125, NSE,SCC and CYFRA21-1 respectively. The sensitivity of MIC-1 for early stage of lung cancer （stage I and stage Ⅱ） was higher than the combination of the above five markers （stage Ⅰ ：66.7% vs 47.6%; stage H ：71.7% vs 65.0%）. The sensitivity for stage Ⅰ and stage Ⅱ reached 77.1% and 83.3% respectively in the combination of the six markers. [Conclusions] Serum MIC-1 level might be an ideal marker in diagnosis for lung cancer.

关 键 词：巨噬细胞抑制因子-1 肿瘤标志物 肺癌 诊断 

分 类 号：R734.2[医药卫生—肿瘤]